Pathogen reduction technologies: The pros and cons for platelet transfusion

Platelets

Volumn 29, Issue 1, 2018, Pages 2-8

  Magron, Audrey ^a   Laugier, Jonathan ^a   Provost, Patrick ^a   Boilard, Eric ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

pathogen reduction systems; platelets; transfusion

Indexed keywords

CYTOKINE; PROTEOME; TRANSCRIPTOME;

CYTOKINE PRODUCTION; LEUKOCYTE; MEMBRANE STRUCTURE; MITOCHONDRION; NONHUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; BLOOD CLOTTING PARAMETERS; BLOOD STORAGE; CYTOLOGY; HUMAN; INFECTION CONTROL; LEUKOCYTE COUNT; MEMBRANE MICROPARTICLE; METABOLISM; PHYSIOLOGY; PROCEDURES; STANDARDS; THROMBOCYTE;

BLOOD PLATELETS; BLOOD PRESERVATION; CELL-DERIVED MICROPARTICLES; CYTOKINES; HUMANS; INFECTION CONTROL; LEUKOCYTE COUNT; MITOCHONDRIA; PLATELET FUNCTION TESTS; PLATELET TRANSFUSION; PROTEOME;

EID: 85041131486     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537104.2017.1306046     Document Type: Review

References (74)

1. Wandt H, Schäfer-Eckart K, Greinacher A., Platelet transfusion in hematology, oncology and surgery. Dtsch Ärztebl Int 2014;111:809.
2. Kleinman S, Chan P, Robillard P., Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003;17:120–162.
3. Katus MC, Szczepiorkowski ZM, Dumont LJ, Dunbar NM., Safety of platelet transfusion: Past, present and future. Vox Sang 2014;107:103–113.
4. Störmer M, Vollmer T., Diagnostic methods for platelet bacteria screening: Current status and developments. Transfus Med Hemotherapy 2014;41:19.
5. Rapport Comité de biovigilance 2012-2013-15-933-05W.pdf. Available at http://publications.msss.gouv.qc.ca/msss/fichiers/2015/15-933-05W.pdf.
6. Benjamin RJ, Dy B, Perez J, Eder AF, Wagner SJ., Bacterial culture of apheresis platelets: A mathematical model of the residual rate of contamination based on unconfirmed positive results. Vox Sang 2014;106:23–30.
7. Prowse CV., Component pathogen inactivation: A critical review. Vox Sang 2013;104:183–199.
8. Schlenke P., Pathogen inactivation technologies for cellular blood components: An update. Transfus. Med Hemotherapy Off Organ Dtsch Ges Transfusionsmedizin Immunhamatologie 2014;41:309–325.
9. Kwon SY, Kim IS, Bae JE, Kang JW, Cho YJ, Cho NS, et al. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 2014;107:254–260.
10. Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion (Paris) 2006;46:1168–1177.
11. TM. Transfus Med Hemotherapy 2011;38:19.
12. Van Rhenen D, Gulliksson H, Cazenave J-P, Pamphilon D, Ljungman P, Klüter H, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood 2003;101:2426–2433.
13. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood 2004;104:1534–1541.
14. Janetzko K, Cazenave J-P, Klüter H, Kientz D, Michel M, Beris P, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion (Paris) 2005;45:1443–1452.
15. Kerkhoffs, J-LH, Van Putten, WLJ, Novotny VMJ, Te Boekhorst, PAW, Schipperus MR, Zwaginga JJ, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010;150:209–217.
16. Lozano M, Knutson F, Tardivel R, Cid J, Maymó RM, Löf H, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011;153:393–401.
17. Kumar V, Lockerble O, Kell SD, Ruane PH, Platz MS, Martin CB, et al. Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2007;80:15–21.
18. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion (Paris) 2010;50:2362–2375.
19. Ambruso, DR, Thurman G, Marschner S, Goodrich RP., Blood components: Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light–treated platelet concentrates. Transfusion (Paris) 2009;49:2631–2636.
20. Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion (Paris) 2009;49:2612–2624.
21. Sandgren P, Tolksdorf F, Struff WG, Gulliksson H., In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-platelets method. Vox Sang 2011;101:35–43.
22. Thiele T, Pohler P, Kohlmann T, Sümnig A, Aurich K, Selleng K, et al. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction: A phase I clinical trial. Vox Sang 2015;109:44–51.
23. 2) for pathogen-reduction. Vox Sang 2009;97:26–33.
24. Johnson L, Loh YS, Kwok M, Marks DC., In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT blood system. Transfus Med 2013;23:121–129.
25. Wagner, SJ, Skripchenko A, Myrup A, Awatefe H, Thompson‐Montgomery D, Moroff G, et al. Evaluation of in vitro storage properties of prestorage pooled whole blood–derived platelets suspended in 100 percent plasma and treated with amotosalen and long‐wavelength ultraviolet light. Transfusion (Paris) 2009;49:704–710.
26. Abonnenc M, Crettaz D, Tacchini P, Di Vincenzo L, Sonego G, Prudent M, et al. Antioxidantpower as a quality control marker for completeness of amotosalen and ultraviolet A photochemical treatments in platelet concentrates and plasma units. Transfusion (Paris) 2016;56:1819–1827.
27. Carvalho H, Alguero C, Santos M, De Sousa G, Trindade H, Seghatchian J., The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience. Transfus Apher Sci 2006;34:187–192.
28. Osman A, Hitzler WE, Meyer CU, Landry P, Corduan A, Laffont B, et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 2015;26:154–163.
29. Stivala S, Gobbato S, Reiner MF, Meyer SC, Lüscher TF, Infanti L, et al. The intercept blood system affects platelet function and survival by inducing apoptosis. Blood 2014;124:4283–4283.
30. Apelseth, TO, Hervig TA, Wentzel-Larsen T, Bruserud Ø., Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion (Paris) 2006;46:800–810.
31. Picker, SM, Speer R, Gathof BS., Functional characteristics of buffy‐coat PLTs photochemically treated with amotosalen‐HCl for pathogen inactivation. Transfusion (Paris) 2004;44:320–329.
32. Abonnenc M, Sonego G, Kaiser-Guignard J, Crettaz D, Prudent M, Tissot J-D, et al. In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: Psoralen-based photochemical treatment step-by-step. Blood Transfus 2015;13: 255.
33. Jansen GAJ, Vliet V, D.M HH, Vermeij H, Beckers EAM, Leebeek FWG, et al. Functional characteristics of photochemically treated platelets. Transfusion (Paris) 2004;44:313–319.
34. Picker, SM, Steisel A, Gathof BS., Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion (Paris) 2008;48:1685–1692.
35. AuBuchon, JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion (Paris) 2005;45:1335–1341.
36. Li J, Lockerbie O, De Korte D, Rice J, McLean R, Goodrich RP., Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion (Paris) 2005;45:920–926.
37. Picker, SM, Steisel A, Gathof BS., Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study. Transfus Apher Sci 2009;40:79–85.
38. Zeddies S, De Cuyper IM, Van Der Meer, PF, Daal BB, De Korte D, Gutiérrez L, et al. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion (Paris) 2014;54:2292–2300.
39. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion (Paris) 2005;45:911–919.
40. Middelburg, RA, Roest M, Ham J, Coccoris M, Zwaginga JJ, Van Der Meer PF. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion (Paris) 2013;53:1780–1787.
41. Ostrowski, SR, Bochsen L, Salado-Jimena JA, Ullum H, Reynaerts I, Goodrich RP, et al. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion (Paris) 2010;50:2210–2219.
42. Picker, SM, Steisel A, Gathof BS., Evaluation of white blood cell- and platelet-derived cytokine accumulation in MIRASOL-PRT-treated platelets. Transfus Med Hemotherapy 2009;36:114.
43. Tauszig, ME, Picker SM, Gathof BS., Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction. Transfus Apher Sci 2012;46:33–37.
44. Seghatchian J, Tolksdorf F., Characteristics of the THERAFLEX UV-platelets pathogen inactivation system: An update. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 2012;46:221–229.
45. Van Aelst B, Devloo R, Vandekerckhove P, Compernolle V, Feys HB., Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro. Transfusion (Paris) 2015;55:2404–2414.
46. Noulsri E, Udomwinijsilp P, Lerdwana S, Chongkolwatana V, Permpikul P., Differences in levels of platelet-derived microparticles in platelet components prepared using the platelet rich plasma, buffy coat, and apheresis procedures. Transfus Apher Sci 2016;16:30149–30150.
47. Melki I, Tessandier N, Zufferey A, Boilard E., Platelet microvesicles in health and disease. Platelets 2017;0:1–8.
48. Nomura S, Okamae F, Abe M, Hosokawa M, Yamaoka M, Ohtani T, et al. Platelets expressing P-selectin and platelet-derived microparticles in stored platelet concentrates bind to PSGL-1 on filtrated leukocytes. Clin Appl Thromb 2000;6:213–221.
49. Boilard E, Blanco P, Nigrovic PA., Platelets: Active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 2012;8:534–542.
50. Diquattro M, De Francisci G, Bonaccorso R, Tagliavia AM, Marcatti M, Palma B, et al. Evaluation of amotosalem treated platelets over 7 days of storage with an automated cytometry assay panel. Int J Lab Hematol 2013;35:637–643.
51. Maurer-Spurej E, Larsen R, Labrie A, Heaton A, Chipperfield K., Microparticle content of platelet concentrates is predicted by donor microparticles and is altered by production methods and stress. Transfus Apher Sci 2016;55:35–43.
52. Li J, De Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: Comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004;87:82–90.
53. Chen Z, Schubert P, Bakkour S, Culibrk B, Busch MP, Devine DV., p38 mitogen-activated protein kinase regulates mitochondrial function and microvesicle release in riboflavin- and ultraviolet light–treated apheresis platelet concentrates. Transfusion (Paris) 2017;5:1199–1207.
54. Johnson L, Hyland R, Tan S, Tolksdorf, F, Sumian C, Seltsam, A, et al. In vitro quality of platelets with low plasma carryover treated with ultraviolet C light for pathogen inactivation. Transfus Med Hemotherapy 2016;43: 190.
55. Hechler B, Ohlmann P, Chafey P, Ravanat C, Eckly A, Maurer E, et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion (Paris) 2013;53:1187–1200.
56. Picker, SM, Oustianskaia L, Schneider V, Gathof BS., Annexin V Release and transmembrane mitochondrial potential during storage of apheresis-derived platelets treated for pathogen reduction. Transfus Med Hemotherapy 2010;37:7.
57. Bruchmüller I, Lösel R, Bugert P, Corash L, Lin L, Klüter H, et al. Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. Platelets 2005;8:441–445.
58. Bakkour S, Chafets DM, Wen L, Dupuis K, Castro G, Green JM, et al. Assessment of nucleic acid modification induced by amotosalen and ultraviolet A light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA. Transfusion (Paris) 2016;56:410–420.
59. Bakkour S, Chafets DM, Wen L, Van Der Meer, PF, Mundt JM, Marschner S, et al. Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light. Vox Sang 2014;107:351–359.
60. Osman A, Hitzler WE, Ameur A, Provost P., Differential expression analysis by RNA-Seq reveals perturbations in the platelet mRNA transcriptome triggered by pathogen reduction systems. Plos ONE 2015;10:e0133070.
61. Marrocco C, D’Alessandro A, Girelli G, Zolla L., Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. Transfusion (Paris) 2013;53:1808–1820.
62. Prudent M, Crettaz D, Delobel J, Tissot J-D, Lion N., Proteomic analysis of Intercept-treated platelets. J Proteomics 2012;76(SpecNo):316–328.
63. Thiele T, Sablewski A, Iuga C, Bakchoul T, Bente A, Görg S, et al. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation: A LC-ESI-MS/MS-based proteomics approach. Blood Transfus Trasfus Sangue 10 Suppl 2012;2:s63–70.
64. Prudent M, Sonego G, Abonnenc M, Tissot J-D, Lion N., LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets. J Am Soc Mass Spectrom 2014;25:651–661.
65. Chen Z, Schubert P, Culibrk B, Devine DV., p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment. Transfusion (Paris) 2015;4:848–857.
66. Schubert P, Coupland D, Culibrk, B, Goodrich RP, Devine DV., Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: Inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion (Paris) 2013;53:3164–3173.
67. Asano H, Lee C-Y, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007;84:1174–1182.
68. Marschner S, Fast LD, Baldwin III WM, Slichter SJ, Goodrich RP., White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion (Paris) 2010;50:2489–2498.
69. Fast, LD, DiLeone G, Li J, Goodrich R., Functional inactivation of white blood cells by Mirasol treatment. Transfusion (Paris) 2006;46:642–648.
70. Truitt, RL, Johnson BD, Hanke C, Talib S, Hearst JE., Photochemical treatment with S-59 Psoralen and Ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 1999;163:5145–5156.
71. Grass, JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180–2188.
72. Hei, DJ, Grass JA, Lin L, Corash L, Cimino GD., Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion (Paris) 1999;39:239–248.
73. Pohler P, Müller M, Winkler C, Schaudien D, Sewald K, Müller TH, et al. Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products. Transfusion (Paris) 2015;55:337–347.
74. Fiebig E, Hirschkorn DF, Maino VC, Grass JA, Lin L, Busch MP., Assessment of donor T-cell function in cellular blood components by the CD69 induction assay: Effects of storage, γ radiation, and photochemical treatment. Transfusion (Paris) 2000;40:761–770